Business
Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™
Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n\n\n\nTetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™\nCanada NewsWire\nOTTAWA, Jan. 31, 2020\n\n\n\nOTTAWA, Jan. 31, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Company\") (TSXV: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received a favorable letter from the United States Food and Drug Administration (\"FDA\") with respect to CAUMZ™.  This follows the Company's previously announced Type B meeting with the FDA for CAUMZ™. The Company will be issuing a news release on Monday, February 3rd, explaining the decisions.\nAbout Tetra Bio-PharmaTetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. Could we work in \"existing regulatory standards of safety and clinical evidence for pharmaceutical products\". \nFor more information visit: www.tetrabiopharma.com\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\nForward-looking statementsSome statements in this release may contain forward-looking i...